BACKGROUND Macrophage activation syndrome(MAS)is defined as a specific secondary hemophagocytic lymphohistiocytosis that refers particularly to those triggered
BACKGROUND Bortezomib is a first-line drug approved for patients with multiple myeloma (MM) and has significantly increased their overall survival. However, bor
BACKGROUND Bowen’s disease (BD) is a persistent, progressive intraepidermal carcinoma. BD usually occurs in areas exposed to sunlight. Involvement of the dorsu